Dalneshia Dewanna Mcneill, | |
1715 Ashley Ave Ste A, Alexandria, LA 71301 | |
(318) 625-7581 | |
(844) 317-5579 |
Full Name | Dalneshia Dewanna Mcneill |
---|---|
Gender | Female |
Speciality | Case Manager/care Coordinator |
Location | 1715 Ashley Ave Ste A, Alexandria, Louisiana |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1497269161 | NPI | - | NPPES |
810729156 | Medicaid | LA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YP2500X | Counselor - Professional | (Louisiana) | Secondary |
171M00000X | Case Manager/care Coordinator | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dalneshia Dewanna Mcneill, 1104 Cedar Ct, Alexandria, LA 71303-5502 Ph: (318) 955-1346 | Dalneshia Dewanna Mcneill, 1715 Ashley Ave Ste A, Alexandria, LA 71301 Ph: (318) 625-7581 |
News Archive
Facial fractures in children occur in different patterns in different age groups, but most often occur with other types of severe injuries, reports a study in the December issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.
With less than half of medications including specific labeling for children, Kathleen Neville, MD, MS, a physician at Children's Mercy Hospital, recently led an American Academy of Pediatrics (AAP) committee in updating the policy with new recommendations guiding the off-label use of drugs in pediatric patients.
New findings by a University of Houston psychology professor indicate that among firefighters, distress tolerance amplifies associations between posttraumatic stress disorder (PTSD) symptoms and alcohol use severity. In the world of psychology, distress tolerance is your actual or perceived ability to withstand emotional distress. It is surviving - and knowing you can survive - an emotional incident.
Solvay has re-evaluated the commercial potential of bifeprunox, a Solvay compound in clinical development for the treatment of schizophrenia . Bifeprunox additionally has the potential to be developed in other disorders, i.e. bipolar disorder.
The majority of advanced cancer patients who experience agitation achieve control after the first dose of an antipsychotic–antiseizure combination is administered, show study results.
› Verified 5 days ago